Review of 14 Randomized Trials Finds CBD Shows Promise for Anxiety and Cognition, But Evidence Is Mixed | Research

The takeaway

CBD showed improvement in anxiety and cognitive impairments in 9 of 16 analyzed trial outcomes, with effective doses ranging from 200-1,500 mg oral or 13.75 mg vaporized, but study design variability limits conclusions.

Clinicians considering CBD for anxiety or cognitive complaints; researchers designing CBD clinical trials.

9 of 16 trial outcomes showed CBD improved anxiety or cognition

What the researchers found

Nine of 16 outcomes across 14 trials showed CBD improved anxiety and cognition. Effective oral doses ranged from 200-1,500 mg (single dose) and 13.75 mg vaporized. CBD had a good safety profile with no addiction behaviors. Non-significant results were attributed to THC masking effects, low doses, unknown CBD purity, and underpowered designs.

Why it matters

Despite widespread consumer use of CBD for cognitive and anxiety issues, the clinical evidence remains surprisingly thin and inconsistent. This review identifies the specific methodological factors that explain the variability, providing a roadmap for designing better trials.

The numbers in context

14 randomized trials reviewed. 9 of 16 outcomes showed improvement. Effective oral doses: 200-1,500 mg single dose. Effective vaporized dose: 13.75 mg. Good safety profile reported across trials. No addiction behaviors observed.

How the study worked

Systematic literature review using PUBMED and university resources. 14 randomized clinical trials selected and compared for design, CBD formulations, populations, and outcomes. Results synthesized conceptually and in summary tables.

What this study cannot tell us

The 14 trials reviewed had highly variable designs, populations, doses, formulations, and outcome measures, making pooled conclusions difficult. Many trials were underpowered. The review does not include a meta-analytic statistical synthesis.

How to read the evidence

Moderate: systematic review of randomized trials, but substantial heterogeneity in study designs and lack of meta-analytic synthesis limit the strength of conclusions.

When this study was published

2024 systematic review.

The bigger picture

As medical cannabis becomes more accessible, the gap between consumer expectations and clinical evidence for CBD's cognitive effects needs to close. This review suggests CBD has genuine cognitive potential but that most existing trials were not designed well enough to detect it consistently.

Questions still open

What is the optimal CBD dose and formulation for cognitive benefits? Could CBD slow cognitive decline in Alzheimer's disease, as the review suggests for future testing? Does chronic CBD dosing produce different cognitive effects than acute administration?

Common questions

What doses of CBD helped with cognition?

Effective single oral doses ranged from 200 to 1,500 mg, with vaporized CBD effective at just 13.75 mg. The wide range reflects different study populations and conditions, and the optimal dose for cognitive benefits has not been established.

Why did some trials show no effect?

The review identified several factors: THC in the formulation may have masked CBD effects, some doses were too low, CBD purity was unknown in some products, and many studies were too small to detect moderate effects statistically.

Read the original research

Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials.

Frontiers in pharmacology, 15, 1403147

View on PubMed ↗Publisher’s paper ↗

Citation

Yndart Arias, Adriana; Vadell, Kamila; Vashist, Arti; Kolishetti, Nagesh; Lakshmana, Madepalli K; Nair, Madhavan; Liuzzi, Juan P. (2024). Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials.. Frontiers in pharmacology, 15, 1403147. https://doi.org/10.3389/fphar.2024.1403147